Tvardi Therapeutics Inc (TVRD)

$2.02 +0.07 (3.59%)
Market Cap 18.95M
Revenue (ttm) 0.00
Net Income (ttm) -18.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 112,100
Avg Vol 186,684
Day's Range N/A - N/A
Shares Out 9.38M
Stochastic %K 42%
Beta 0.39
Analysts Sell
Price Target $8.29

Company Profile

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 489 8654
Address:
3 Sugar Creek Center Boulevard, Suite 525, Sugar Land, United States
trt102967
trt102967 Jul. 4 at 3:13 PM
$TVRD Fasten your seatbelts. Results could be any day. Let’s see them Monday PM!!
0 · Reply
LeftyTwit
LeftyTwit Jul. 2 at 10:20 PM
$TVRD I ducked out at 2.05 and took the gain.
0 · Reply
stockusfrance
stockusfrance Jul. 2 at 6:20 PM
$TVRD There are several structural factors that make a short squeeze on TVRD plausible. The company has a very small free float (~6.2M shares), which increases price sensitivity to buying pressure. Current data shows short interest exceeding 10% of the float, combined with a days‑to‑cover ratio above 15, indicating that short sellers would struggle to exit quickly if momentum shifts. While a squeeze requires a catalyst, the underlying conditions suggest that TVRD is a stock where a #ShortSqueeze could occur under the right circumstances.
0 · Reply
stockusfrance
stockusfrance Jul. 2 at 6:19 PM
$TVRD Keep an eye on $TVRD — this ticker has all the ingredients for a potential #ShortSqueeze. The float is tiny (~6M shares), the short interest is climbing, and the days‑to‑cover is unusually high. In a low‑float biotech, it doesn’t take much: one news catalyst, one volume spike, and shorts can get forced to cover in panic. Not saying it will happen — but the setup is there, and it’s getting interesting.
0 · Reply
stockusfrance
stockusfrance Jul. 2 at 6:18 PM
$TVRD A short squeeze on $TVRD is absolutely possible. The stock has a tiny float of around 6.2M shares, which means any surge in buying pressure can move the price fast. On top of that, the short interest is rising, with more than 10% of the float sold short and a days-to-cover ratio above 15. When a low‑float biotech with high volatility starts attracting attention, shorts can get trapped quickly. If volume spikes or a positive catalyst hits, TVRD could become a perfect setup for a #ShortSqueeze.
0 · Reply
stockusfrance
stockusfrance Jul. 2 at 4:52 PM
$TVRD Going to close Red ?
0 · Reply
creyl
creyl Jul. 2 at 3:06 PM
$TVRD 🤔🤔
1 · Reply
stockusfrance
stockusfrance Jul. 2 at 2:21 PM
$TVRD Do not sell for 1 or 2% when u can make +500%
0 · Reply
stockusfrance
stockusfrance Jul. 2 at 2:07 PM
$TVRD Burn shorties
0 · Reply
trt102967
trt102967 Jul. 2 at 1:53 PM
$TVRD It takes almost no volume at all to move this quick. Wait until the drop great test results PR!!! Let’s push back to $40+
0 · Reply
Latest News on TVRD
Tvardi Therapeutics initiated with a Buy at H.C. Wainwright

2026-06-08T10:20:08.000Z - 26 days ago

Tvardi Therapeutics initiated with a Buy at H.C. Wainwright

Tvardi Therapeutics to Participate in Upcoming Investor Events

May 21, 2026, 8:00 AM EDT - 6 weeks ago

Tvardi Therapeutics to Participate in Upcoming Investor Events

Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)

2026-05-08T11:14:39.000Z - 2 months ago

Tvardi Therapeutics reports Q1 EPS (73c), consensus (72c)

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

May 8, 2026, 7:00 AM EDT - 2 months ago

Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update

Tvardi Therapeutics files $200M mixed securities shelf

2026-05-01T20:11:24.000Z - 2 months ago

Tvardi Therapeutics files $200M mixed securities shelf

Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays

2026-04-20T09:26:43.000Z - 2 months ago

Tvardi Therapeutics downgraded to Underweight from Equal Weight at Barclays

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Apr 2, 2026, 8:00 AM EDT - 3 months ago

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler

2026-04-01T11:13:02.000Z - 3 months ago

Tvardi Therapeutics price target lowered to $3 from $4 at Piper Sandler

Tvardi Therapeutics price target lowered to $4 from $5 at Barclays

2026-04-01T10:34:44.000Z - 3 months ago

Tvardi Therapeutics price target lowered to $4 from $5 at Barclays

Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)

2026-03-31T20:06:37.000Z - 3 months ago

Tvardi Therapeutics reports Q4 EPS (78c), consensus (57c)

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Mar 31, 2026, 4:01 PM EDT - 3 months ago

Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update

Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital

2026-02-04T11:11:35.000Z - 5 months ago

Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 4:05 PM EST - 6 months ago

Tvardi Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Tvardi Therapeutics announces further Phase 2 REVERT IPF data

2026-01-08T13:25:58.000Z - 6 months ago

Tvardi Therapeutics announces further Phase 2 REVERT IPF data

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 8 months ago

Tvardi Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)

2025-11-13T21:06:01.000Z - 8 months ago

Tvardi Therapeutics reports Q3 EPS (59c), consensus (96c)

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Nov 13, 2025, 4:01 PM EST - 8 months ago

Tvardi Therapeutics Announces Third Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Nov 4, 2025, 8:00 AM EST - 8 months ago

Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Tvardi downgraded to Market Perform from Outperform at Raymond James

2025-10-14T11:00:22.000Z - 9 months ago

Tvardi downgraded to Market Perform from Outperform at Raymond James

Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays

2025-10-13T20:15:10.000Z - 9 months ago

Tvardi Therapeutics downgraded to Equal Weight from Overweight at Barclays

Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’

2025-10-13T14:35:06.000Z - 9 months ago

Cantor downgrades Tvardi Therapeutics, sees ‘no path forward in IPF’

Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

2025-10-13T14:15:14.000Z - 9 months ago

Tvardi Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald

Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler

2025-10-13T14:10:07.000Z - 9 months ago

Tvardi Therapeutics downgraded to Neutral from Overweight at Piper Sandler

Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?

2025-10-13T12:53:44.000Z - 9 months ago

Why Is Tvardi Therapeutics Stock (TVRD) Down 85% Today?

Tvardi says benefit of TTI-101 treatment not observed in REVERT trial

2025-10-13T11:51:36.000Z - 9 months ago

Tvardi says benefit of TTI-101 treatment not observed in REVERT trial

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Oct 13, 2025, 7:30 AM EDT - 9 months ago

Tvardi Therapeutics Provides Update on Preliminary Data from Phase 2 REVERT Trial in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 21, 2025, 8:00 AM EDT - 11 months ago

Tvardi Therapeutics to Participate in the Cantor Global Healthcare Conference

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

Aug 14, 2025, 4:01 PM EDT - 11 months ago

Tvardi Therapeutics Announces Second Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:00 AM EDT - 1 year ago

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025, 8:00 AM EDT - 1 year ago

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

May 20, 2025, 8:00 AM EDT - 1 year ago

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 1 year ago

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

May 6, 2025, 7:00 AM EDT - 1 year ago

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Apr 15, 2025, 4:05 PM EDT - 1 year ago

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

CARA

trt102967
trt102967 Jul. 4 at 3:13 PM
$TVRD Fasten your seatbelts. Results could be any day. Let’s see them Monday PM!!
0 · Reply
LeftyTwit
LeftyTwit Jul. 2 at 10:20 PM
$TVRD I ducked out at 2.05 and took the gain.
0 · Reply
stockusfrance
stockusfrance Jul. 2 at 6:20 PM
$TVRD There are several structural factors that make a short squeeze on TVRD plausible. The company has a very small free float (~6.2M shares), which increases price sensitivity to buying pressure. Current data shows short interest exceeding 10% of the float, combined with a days‑to‑cover ratio above 15, indicating that short sellers would struggle to exit quickly if momentum shifts. While a squeeze requires a catalyst, the underlying conditions suggest that TVRD is a stock where a #ShortSqueeze could occur under the right circumstances.
0 · Reply
stockusfrance
stockusfrance Jul. 2 at 6:19 PM
$TVRD Keep an eye on $TVRD — this ticker has all the ingredients for a potential #ShortSqueeze. The float is tiny (~6M shares), the short interest is climbing, and the days‑to‑cover is unusually high. In a low‑float biotech, it doesn’t take much: one news catalyst, one volume spike, and shorts can get forced to cover in panic. Not saying it will happen — but the setup is there, and it’s getting interesting.
0 · Reply
stockusfrance
stockusfrance Jul. 2 at 6:18 PM
$TVRD A short squeeze on $TVRD is absolutely possible. The stock has a tiny float of around 6.2M shares, which means any surge in buying pressure can move the price fast. On top of that, the short interest is rising, with more than 10% of the float sold short and a days-to-cover ratio above 15. When a low‑float biotech with high volatility starts attracting attention, shorts can get trapped quickly. If volume spikes or a positive catalyst hits, TVRD could become a perfect setup for a #ShortSqueeze.
0 · Reply
stockusfrance
stockusfrance Jul. 2 at 4:52 PM
$TVRD Going to close Red ?
0 · Reply
creyl
creyl Jul. 2 at 3:06 PM
$TVRD 🤔🤔
1 · Reply
stockusfrance
stockusfrance Jul. 2 at 2:21 PM
$TVRD Do not sell for 1 or 2% when u can make +500%
0 · Reply
stockusfrance
stockusfrance Jul. 2 at 2:07 PM
$TVRD Burn shorties
0 · Reply
trt102967
trt102967 Jul. 2 at 1:53 PM
$TVRD It takes almost no volume at all to move this quick. Wait until the drop great test results PR!!! Let’s push back to $40+
0 · Reply
Twit_2_my_lou
Twit_2_my_lou Jul. 2 at 1:06 PM
$TVRD I guess no news today. Maybe 9:30?
0 · Reply
Twit_2_my_lou
Twit_2_my_lou Jul. 2 at 12:48 PM
$TVRD Tradingview has no trades since 5:10am this morning. That's so strange. Why isn't the chart being updated?
1 · Reply
Fakhrul123
Fakhrul123 Jul. 1 at 10:21 PM
$TVRD
0 · Reply
Jonnyp2020
Jonnyp2020 Jul. 1 at 7:37 PM
$TVRD someone break down what’s happening here?
0 · Reply
trt102967
trt102967 Jul. 1 at 7:03 PM
$TVRD
0 · Reply
topstockalerts
topstockalerts Jul. 1 at 6:16 PM
$TVRD send it!!
1 · Reply
stockusfrance
stockusfrance Jul. 1 at 5:25 PM
$TVRD
0 · Reply
stockusfrance
stockusfrance Jul. 1 at 3:00 PM
$TVRD In the best case, we could reach the gap at $40. Everything is possible, just look $SDOT. She shows us the way. Patience
0 · Reply
LeftyTwit
LeftyTwit Jul. 1 at 2:51 PM
$TVRD nice recovery
0 · Reply
stockusfrance
stockusfrance Jul. 1 at 2:43 PM
$TVRD It's not sure that if you go elsewhere you'll make money. You could also lose some. So you might as well wait here it's less risky
0 · Reply
Ozcorp
Ozcorp Jul. 1 at 1:42 PM
$TVRD I’m out no news and it’s a red day. Not risking it going back down to $1.80. Good luck to all the longer the news comes out the less of a run. They promised June and didn’t deliver
1 · Reply
Ozcorp
Ozcorp Jul. 1 at 12:44 PM
$TVRD I was weak and didn’t sell so there better be damn good nnews
0 · Reply